阿尔茨海默病：索拉珠单抗——对阿尔茨海默病进行有效干预的前景？
Alzheimer disease: Solanezumab-prospects for meaningful interventions in AD?
作者信息
Gandy Sam, Sano Mary
机构信息
Alzheimer's Disease Research Center, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.
出版信息
Nat Rev Neurol. 2015 Dec;11(12):669-70. doi: 10.1038/nrneurol.2015.218. Epub 2015 Nov 3.
Abstract
A treatment trial of the monoclonal anti-amyloid antibody solanezumab showed slight benefits in people with dementia due to mild Alzheimer disease. Drug effects on several neuropsychological testing outcomes were statistically significant, but the effect sizes were unlikely to manifest as meaningful functional benefits. Here, we discuss the implications and possible molecular underpinnings.
摘要
一项针对单克隆抗淀粉样蛋白抗体索拉珠单抗的治疗试验表明，对于轻度阿尔茨海默病所致痴呆患者有轻微益处。药物对多项神经心理学测试结果的影响具有统计学意义，但效应大小不太可能转化为有意义的功能益处。在此，我们讨论其意义及可能的分子基础。
相似文献
1
Alzheimer disease: Solanezumab-prospects for meaningful interventions in AD?阿尔茨海默病：索拉珠单抗——对阿尔茨海默病进行有效干预的前景？
Nat Rev Neurol. 2015 Dec;11(12):669-70. doi: 10.1038/nrneurol.2015.218. Epub 2015 Nov 3.
2
Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid β monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease.日本和白人轻度至中度阿尔茨海默病患者中淀粉样β单克隆抗体索拉珠单抗的药代动力学、药效学、安全性及耐受性比较
Clin Neuropharmacol. 2012 Jan-Feb;35(1):25-9. doi: 10.1097/WNF.0b013e31823a13d3.
3
Targeting amyloid β in Alzheimer's disease: Meta-analysis of low-dose solanezumab in Alzheimer's disease with mild dementia studies.针对阿尔茨海默病中的淀粉样β：轻度痴呆阿尔茨海默病低剂量 solanezumab 的荟萃分析研究。
Alzheimers Dement. 2023 Oct;19(10):4619-4628. doi: 10.1002/alz.13031. Epub 2023 Mar 22.
4
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.三期 solanezumab 试验：轻度阿尔茨海默病患者的次要结局。
Alzheimers Dement. 2016 Feb;12(2):110-120. doi: 10.1016/j.jalz.2015.06.1893. Epub 2015 Aug 1.
5
Solanezumab for the treatment of mild-to-moderate Alzheimer's disease.用于治疗轻度至中度阿尔茨海默病的 Solanezumab。
Expert Rev Clin Immunol. 2012 Feb;8(2):135-49. doi: 10.1586/eci.11.93.
6
Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N‑truncated Abeta in sporadic Alzheimer disease cases and mouse models.比较针对淀粉样蛋白β的生物类似抗体 Bapineuzumab、Crenezumab、Solanezumab 和针对 N 端截断淀粉样蛋白β的抗体在散发性阿尔茨海默病病例和小鼠模型中的作用。
Acta Neuropathol. 2015 Nov;130(5):713-29. doi: 10.1007/s00401-015-1489-x.
7
Lessons learned from the failure of solanezumab as a prospective treatment strategy for Alzheimer's disease.从用于阿尔茨海默病的潜在治疗策略的 solanezumab 失败中吸取的经验教训。
Expert Opin Drug Discov. 2024 Jun;19(6):639-647. doi: 10.1080/17460441.2024.2348142. Epub 2024 Apr 29.
8
Review of the advances in treatment for Alzheimer disease: Strategies for combating β-amyloid protein.阿尔茨海默病治疗进展综述：对抗β-淀粉样蛋白的策略
Neurologia (Engl Ed). 2018 Jan-Feb;33(1):47-58. doi: 10.1016/j.nrl.2015.03.012. Epub 2015 May 11.
9
Grasping at straws: the failure of solanezumab to modify mild Alzheimer's disease.抓救命稻草：索拉珠单抗未能改善轻度阿尔茨海默病。
Expert Opin Biol Ther. 2018 Dec;18(12):1189-1192. doi: 10.1080/14712598.2018.1543397. Epub 2018 Nov 9.
10
Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?用于治疗阿尔茨海默病的淀粉样蛋白导向单克隆抗体：是否已到不可逆转的地步？
Expert Opin Biol Ther. 2014 Oct;14(10):1465-76. doi: 10.1517/14712598.2014.935332. Epub 2014 Jun 30.
引用本文的文献
1
Functionalization strategies of polymeric nanoparticles for drug delivery in Alzheimer's disease: Current trends and future perspectives.用于阿尔茨海默病药物递送的聚合物纳米颗粒功能化策略：当前趋势与未来展望
Front Neurosci. 2022 Aug 4;16:939855. doi: 10.3389/fnins.2022.939855. eCollection 2022.
2
Alzheimer's Disease-Related Metabolic Pattern in Diverse Forms of Neurodegenerative Diseases.多种神经退行性疾病中与阿尔茨海默病相关的代谢模式
Diagnostics (Basel). 2021 Nov 1;11(11):2023. doi: 10.3390/diagnostics11112023.
3
New treatment modalities in Alzheimer's disease.阿尔茨海默病的新治疗方式。
World J Clin Cases. 2019 Jul 26;7(14):1764-1774. doi: 10.12998/wjcc.v7.i14.1764.
4
The Role of microRNAs in Alzheimer's Disease and Their Therapeutic Potentials.微小RNA在阿尔茨海默病中的作用及其治疗潜力
Genes (Basel). 2018 Mar 21;9(4):174. doi: 10.3390/genes9040174.
5
Alzheimer's disease hypothesis and related therapies.阿尔茨海默病假说及相关疗法。
Transl Neurodegener. 2018 Jan 30;7:2. doi: 10.1186/s40035-018-0107-y. eCollection 2018.
6
Effective anti-Alzheimer Aβ therapy involves depletion of specific Aβ oligomer subtypes.有效的抗阿尔茨海默病 Aβ 疗法涉及特定 Aβ 寡聚物亚型的耗竭。
Neurol Neuroimmunol Neuroinflamm. 2016 May 10;3(3):e237. doi: 10.1212/NXI.0000000000000237. eCollection 2016 Jun.
本文引用的文献
1
GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP.阿尔茨海默病中18F-氟代贝他吡PET纵向淀粉样蛋白积累的全基因组关联研究表明小胶质细胞激活基因IL1RAP有牵连。
Brain. 2015 Oct;138(Pt 10):3076-88. doi: 10.1093/brain/awv231. Epub 2015 Aug 11.
2
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.三期 solanezumab 试验：轻度阿尔茨海默病患者的次要结局。
Alzheimers Dement. 2016 Feb;12(2):110-120. doi: 10.1016/j.jalz.2015.06.1893. Epub 2015 Aug 1.
3
Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials.两项巴匹兹umab 3期阿尔茨海默病随机试验的淀粉样蛋白β 11C-PiB-PET成像结果。
Neurology. 2015 Aug 25;85(8):692-700. doi: 10.1212/WNL.0000000000001877. Epub 2015 Jul 24.
4
Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.无痴呆症人群中脑淀粉样病变的患病率：一项荟萃分析。
JAMA. 2015 May 19;313(19):1924-38. doi: 10.1001/jama.2015.4668.
5
The A4 study: stopping AD before symptoms begin?A4研究：在症状出现前阻止阿尔茨海默病？
Sci Transl Med. 2014 Mar 19;6(228):228fs13. doi: 10.1126/scitranslmed.3007941.
6
Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.淀粉样蛋白对从临床前阿尔茨海默病到临床阿尔茨海默病的记忆和非记忆下降的影响。
Brain. 2014 Jan;137(Pt 1):221-31. doi: 10.1093/brain/awt286. Epub 2013 Oct 30.
7
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease.对 74046 人的荟萃分析确定了 11 个阿尔茨海默病的新易感性位点。
Nat Genet. 2013 Dec;45(12):1452-8. doi: 10.1038/ng.2802. Epub 2013 Oct 27.
8
Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity.淀粉样蛋白优先和神经退行性变优先特征描述了淀粉样蛋白 PET 阳性的发病情况。
Neurology. 2013 Nov 12;81(20):1732-40. doi: 10.1212/01.wnl.0000435556.21319.e4. Epub 2013 Oct 16.
9
Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers.在存在淀粉样蛋白病理生物标志物的情况下，北极 APP 突变携带者的 PiB PET 保留率较低。
Neurology. 2012 Jul 17;79(3):229-36. doi: 10.1212/WNL.0b013e31825fdf18. Epub 2012 Jun 13.
10
Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.源自β淀粉样蛋白1-42的可扩散、非纤维状配体是强效中枢神经系统神经毒素。
Proc Natl Acad Sci U S A. 1998 May 26;95(11):6448-53. doi: 10.1073/pnas.95.11.6448.
Zotero 插件